CompanyBCDANasdaqSunnyvale, CA

BioCardia, Inc.

BioCardia develops autologous and allogeneic cell therapies for cardiovascular and pulmonary disease.

SEC EDGAR ClinicalTrials.gov biocardia.com

8-KOct 1Latest SEC filing

Oct 1Latest story

October 2026

BioCardia submits revised FDA pre-submission for Helix catheter

Oct 1Regulatory decisionBioCardia, Inc.

September 2026

BioCardia to present CardiAMP and Helix updates at H.C. Wainwright conference

Sep 10PeopleBioCardia, Inc.

August 2026

BioCardia says FDA finalized minutes on Helix catheter pre-submission meeting

Aug 24Regulatory decisionBioCardia, Inc.

BioCardia gets positive regulator signals in Japan and US for CardiAMP and Helix

Aug 12Quarterly updateBioCardia, Inc.